HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractory (R/R) Settings
"HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractory (R/R) Settings" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Olga Ryan
- Bhavini Srivastava
- Monika Salkar (ORCID: https://orcid.org/0000-0002-4198-9711)
- Shaffee Bacchus
- Huimin Li (ORCID: https://orcid.org/0000-0002-6846-2610)
- Pam Martin
- Samuel Crawford
- J.C. Gahn
Institutions
- AbbVie (United States) (US)
- Medical Decision Modeling (United States) (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7351
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63